Inobrodib with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, open-label, multicenter trial enrolling about 100 adults with relapsed or refractory multiple myeloma who are refractory to at least one proteasome inhibitor, one anti‑CD38 antibody and to pomalidomide and who have previously received a bispecific T‑cell engager. Participants receive inobrodib 20 mg orally twice daily on a 4 days on / 3 days off schedule each 28‑day cycle alongside standard-dose pomalidomide (4 mg days 1–21) and dexamethasone (40 mg weekly). Treatment continues until disease progression, unacceptable toxicity, or other withdrawal criteria. The primary endpoint is objective response rate by IMWG criteria as reviewed by an independent committee, with safety and tolerability also closely monitored.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female ≥18 years of age
* Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
* Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
* Adequate hematological, renal and hepatic function
* Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners

Exclusion Criteria:

* Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest
* Prior treatment with p300/CBP bromodomain inhibitors
* Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
* Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
* Major surgery within 4 weeks of the first dose of study treatment
* Live vaccine within 4 weeks of study treatment
* Active or unresolved adverse events
* Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
* Female patients who are pregnant or breast-feeding at any time during the study
* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

Where it's running

• Mayo Clinic Arizona
  Phoenix, Arizona, United States Recruiting
• University of California, San Francisco
  San Francisco, California, United States Recruiting
• Mayo Clinic Florida
  Jacksonville, Florida, United States Recruiting
• H Lee Moffitt Cancer Center & Research Institute
  Tampa, Florida, United States Recruiting
• Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• University of Chicago Medical Center
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: CCS1477-04 Clinical Operations
• Email: DOMMINO-1@cellcentric.com
• Phone: +44 1799 531130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• Inobrodib with Pomalidomide and Dexamethasone vs Standard Therapy for Relapsed or Refractory Myeloma

  This study tests whether inobrodib with pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma more than the standard available therapy.

  Recruiting Phase 3 CellCentric Ltd. · Miami, Florida · NCT07772024

• CAR-T therapy for relapsed or refractory multiple myeloma

  This study tests a CAR-T therapy in people with multiple myeloma whose disease has come back or not responded to treatment.

  Recruiting at 2 sites Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi, Punjab Province and 1 other locations · NCT07689058

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Liposomal Curcumin in Multiple Myeloma: safety and dose finding

  This trial tests a novel liposomal curcumin infusion to see if it is safe and what highest tolerable dose is for adults whose multiple myeloma has returned or not responded to treatment.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT07456605

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.